Cypherpunk Technologies Inc. operates with a unique dual-strategy business model, combining a digital asset treasury strategy with clinical-stage biopharmaceutical development. The company's primary financial strategy involves accumulating Zcash (ZEC) as a core treasury asset and investing in the Zcash ecosystem and other privacy-enhancing technologies. As of early 2026, the company held over 294,000 ZEC, representing a significant portion of its total assets. Operationally, the company continues its legacy biotechnology business through its wholly-owned subsidiary, Leap Therapeutics. This division focuses on developing targeted and immuno-oncology therapeutics. Its lead clinical candidate is sirexatamab (DKN-01), a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, which is in clinical trials for the treatment of esophagogastric, gynecologic, and colorectal cancers. The pipeline also includes FL-501, a preclinical monoclonal antibody designed to inhibit the GDF-15 protein for treating cancer cachexia. The company currently generates no product revenue and funds its operations and digital asset purchases through private placements and equity offerings.
